Evaluate the Safety, Tolerability and Pharmacokinetics of BG00010 (Neublastin) Administered to Sciatica Participants
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine the safety/tolerability profile, systemic
PK behavior, and immunogenicity of single IV and SC administrations of BG00010 to sciatica
participants.